Stereotaxis Announces FDA Clearance and Launch of Synchrony System
Rhea-AI Summary
Stereotaxis (NYSE: STXS) announced FDA 510(k) clearance and commercial launch of the Synchrony system on April 6, 2026. Synchrony is a 55" 4K interventional lab display with ultra-low latency video, obsolescence protection, and cloud-based SynX for HIPAA/GDPR-compliant remote collaboration.
The company reiterated guidance of over $3 million in 2026 revenue from Synchrony placements independent of robotic systems and emphasized future AI-enabled applications and broader cath lab adoption.
Positive
- FDA 510(k) clearance for Synchrony on April 6, 2026
- Reiterated >$3 million 2026 revenue guidance for Synchrony placements
- SynX cloud is HIPAA and GDPR compliant for remote collaboration
- 55" 4K ultra‑low latency display with obsolescence protection
Negative
- Guidance limited to >$3M in Synchrony revenue for 2026
- Company warns it may not recognize revenue from customer orders
- Adoption reliant on customer acceptance and economic conditions
News Market Reaction – STXS
In the Apr 6 session, STXS gained 0.53%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial,fda approval Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | GenesisX FDA clearance | Positive | +2.1% | U.S. FDA 510(k) clearance for GenesisX robotic navigation system. |
| Jul 28 | MAGiC Sweep clearance | Positive | +15.1% | FDA 510(k) clearance for MAGiC Sweep high-density mapping catheter. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent FDA 510(k) clearances in this name have typically been followed by positive single- to mid-teens percentage moves.
Over the past year, Stereotaxis has steadily expanded its FDA-cleared portfolio. The company gained U.S. 510(k) clearance for GenesisX on Nov 10, 2025 and for the MAGiC Sweep mapping catheter on Jul 28, 2025, with both events generating positive share reactions. Today’s Synchrony 510(k) clearance and launch extends that regulatory momentum into lab digitization and connectivity, complementing prior robotics and catheter approvals.
Key Terms
510(k) clearance regulatory
hipaa regulatory
gdpr regulatory
endovascular medical
electrophysiology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system.
Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab, offering an enhanced procedure experience with custom layouts, streamlined workflows, an intuitive user interface, and a decluttered environment. Synchrony digitizes the video streams with full fidelity and ultra-low latency, offering crystal-clear visualization. Its architecture allows obsolescence protection for labs as new technologies are introduced in the future. Synchrony is made available with SynX™, a cloud-based HIPAA and GDPR-compliant app that allows for secure remote connectivity, collaboration, recording, and monitoring of the cath lab.
“We have long recognized that seamless remote connectivity and collaboration for our EP labs could be very beneficial,” said Dr. Mauricio Arruda, Professor of Medicine at Case Western Reserve University School of Medicine and Director of Electrophysiology at University Hospitals Harrington Heart & Vascular Institute. “We are particularly interested in being early pioneers of Synchrony and SynX, and look forward to demonstrating that intraoperative collaboration enhances our ability to provide the best patient care and train the next generation of physicians.”
“We are excited by this technology and the opportunity to be among the first to modernize our catheter labs with Synchrony and SynX when the Richard M. Schulze Surgical and Critical Care Center at Abbott Northwestern Hospital opens in late August,” said Daniel Melby, MD, Medical Director of Electrophysiology Labs at Allina Health Minneapolis Heart Institute. “Our cardiology labs have become increasingly busy and complex environments, accentuating the value of technology that enhances procedure workflow, improves lab efficiency and encourages collaboration.”
“In my role managing the technology across our electrophysiology labs and advising labs across the country, I have significant experience with various interventional lab display offerings,” said Matthew Dare, CEPS, Research and Technology Coordinator, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas. “The underlying hardware and software architecture of Synchrony and SynX is far beyond what anyone else has developed. It promises a better intraoperative experience for physicians and nurses, improved equipment reliability and maintenance, and attractive tools for managing a cardiovascular program with remote monitoring, collaboration and recordings.”
Stereotaxis is reiterating its guidance of over
"Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with enhanced workflow, remote connectivity, and smart AI capabilities,” said David Fischel Stereotaxis Chairman and CEO. “The technology improves the robotic cockpit, and will be critical in supporting robotic efforts for remote long-distance procedures and automated catheter navigation. The opportunity is much broader than robotic labs as we believe all cath labs stand to benefit from improved workflow, connectivity, and collaboration.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
